Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AuM Update

16 Jan 2026 07:00

RNS Number : 1442P
Polar Capital Holdings PLC
16 January 2026
 

16 January 2026 Polar Capital Holdings plc

AuM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist active asset management group, today provides an update in respect of the three months to 31 December 2025.

 

Group AuM (unaudited)

 

Polar Capital reports that as at 31 December 2025 its AuM was £28.4bn compared to £26.7bn at the end of September 2025, an increase of 6% over the quarter. In the quarter, AuM increased by fund performance and market movements of £1.7bn, net inflows of £149m, offset by fund closures of £62m and a £116m return of capital following a third and final investment trust corporate action for the year.

 

AuM movement in three months to 31 December 2025

Open ended

Funds

(£m)

Investment

Trusts

(£m)

Segregated mandates

(£m)

Total

(£m)

AuM at 1 Oct 2025

 

19,905

 

6,294

501

26,700

Net flows

 

233

 

 

(115)

 

 

31

 

 

149

 

Corporate action1

 

-

 

 

(116)

 

 

-

 

 

(116)

 

Fund closures2

 

(62)

 

 

-

 

 

-

 

 

(62)

 

Market movement

and performance

 

1,290

 

 

419

 

 

7

 

 

1,716

 

Total AuM at

31 December 2025

 

21,366

 

6,482

539

28,387

 

AuM movement in nine months to 31 December 2025

Open ended

Funds

(£m)

Investment

Trusts

(£m)

Segregated mandates

(£m)

Total

(£m)

AuM at 1 April 2025

15,994

 

4,846

569

21,409

Net flows

(153)

 

(232)

(156)

(541)

Corporate action1

 

-

 

(396)

-

(396)

Fund closures2

 

(62)

 

 

-

 

 

-

 

 

(62)

 

Market movement

and performance

5,587

2,264

126

7,977

Total AuM at

31 December 2025

21,366

 

6,482

539

28,387

1 Return of capital to investors in June 2025 as the Polar Capital Global Financials Trust underwent a 100% tender offer following which 44% of issued capital was tendered and in November 2025 when Polar Capital Global Healthcare Trust underwent a 100% tender offer following which 22% of issued capital was tendered.

2 Return of funds to investors upon the closure of Polar Capital Melchior European Opportunities Fund in November 2025.

 

Net performance fee profits (unaudited)

 

The table below sets out the position relating to net performance fee profits (after the deduction of staff interests) earned in the first nine months of the Group's financial year.

 

Performance fees

net of staff allocations (All figures in £m)

12 months to

31 Mar 25

(year-end)

Nine months to

31 Dec 25

Total net performance fee profits

7.9

16.0*

\* The figures exclude £1.6m of net performance fee distributions (staff allocations) that are deferred into future periods for accounting purposes, and which should be deducted from the total performance fee profit figure for the purposes of calculating adjusted total earnings per share.

 

Iain Evans, Chief Executive, commented:

"It was a positive end to 2025 for the firm. We delivered net inflows during the quarter and performance fees crystallised above the level accrued at the end of September 2025 and the prior year. The elevated performance fee profits have supported the Board's decision to announce a £15m share buyback programme, signalling confidence in the business and reflecting our disciplined approach to capital allocation, as well as our focus on delivering long-term value for shareholders.

 

"Details of the share buyback programme can be found in a separate announcement released today.

 

"Assets under management rose by 6% over the quarter to £28.4bn, up from £26.7bn at the end of September (£21.4bn at the end of March 2025). The increase was driven by £1.7bn of fund performance and market movements and £149m of net inflows, partly offset by £62m relating to the closure of the Polar Capital Melchior European Opportunities Fund and a £116m one-off return of capital following the Polar Capital Global Healthcare Trust corporate action.

 

"Net outflows, excluding the impact of fund closures, in October (£9m) and November (£138m) were followed by a sharp reversal in December, when 10 investment teams recorded net inflows totalling £296m across all strategies. Overall, the quarter compares favourably with the comparable period in the prior year, when net outflows were £260m.

 

"Performance fee profits (net of staff allocations), crystallised at the end of December 2025, amounted to £16m. This compares with accruals of £15m at the end of September 2025 and £7.9m crystallised in the prior year. The profits were generated predominantly by the Biotech, Healthcare Opportunities and the two Convertible Bond funds, with smaller contributions from the Artificial Intelligence, Healthcare Blue Chip and Japan Value funds.

 

Outlook

"2025 remained a challenging backdrop for active equity managers, with investor outflows continuing at elevated levels.

 

"Although higher rates, volatility and broader dispersion would typically favour high-conviction active strategies, market leadership remained unusually concentrated for much of the year, making consistent outperformance difficult for many diversified approaches. Independent data indicates that, in aggregate, fewer than a third of active managers globally outperformed in 2025*.

 

"Against that backdrop, Polar Capital performed well on a relative basis. Two-thirds of our strategies (UCITS and investment trusts) outperformed their respective benchmarks, with standout results in Convertible Bonds, Technology, Healthcare and Biotech, Japan Value, and Smart Energy. We also completed three successful investment trust corporate actions - an exceptional outcome that reflects the strength of our brand, our investment capability and our client relationships, and above all the efforts of colleagues across the business.

 

"Encouragingly, client engagement has improved, and the new business pipeline is strengthening. While visibility on the timing and scale of inflows is limited, our priority for 2026 is to convert gross demand into durable net inflows through consistent investment performance, excellent client service and disciplined commercial execution.

 

"Looking ahead, while the external environment is likely to remain uncertain in the near term, I am confident that specialist firms like ours are well placed and that we will continue to adapt, develop and grow."

 

*Source: Baird, Bloomberg, December 2025

 

For further information please contact:

 

Polar Capital

Iain Evans (Chief Executive)Samir Ayub (Chief Financial Officer)

+44 (0)20 7227 2700

 

Deutsche Numis - Nomad and Joint Broker

Giles Rolls

Charles Farquhar

 

+44 (0)20 7260 1000

 

 

Peel Hunt LLP - Joint Broker

Andrew Buchanan

Thomas Philpott

 

 

+44 (0)20 3597 8680

Camarco - PR

Ed Gascoigne-Pees

Jennifer Renwick

Phoebe Pugh

+44 (0)20 3757 4980

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAAFSFSXKEAA
Date   Source Headline
4th Feb 20199:43 amRNSBlock listing Interim Review
1st Feb 201911:41 amRNSTotal Voting Rights
29th Jan 20194:41 pmRNSSecond Price Monitoring Extn
29th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20195:45 pmRNSIssue of Equity
28th Jan 20195:30 pmRNSDirector/PDMR Shareholding
10th Jan 201910:19 amRNSDirector/PDMR Shareholding
10th Jan 20197:00 amRNSAUM Update
2nd Jan 20199:49 amRNSTotal Voting Rights
12th Dec 20184:00 pmRNSIssue of Equity
27th Nov 20184:40 pmRNSSecond Price Monitoring Extn
27th Nov 20184:35 pmRNSPrice Monitoring Extension
26th Nov 20187:00 amRNSUnaudited Interim Results
22nd Nov 20185:00 pmRNSDirectorate Change
5th Nov 20187:01 amRNSNotice of Results
5th Nov 20187:00 amRNSChange of Nominated Adviser and Broker
1st Nov 20187:00 amRNSTotal Voting Rights
25th Oct 20185:26 pmRNSIssue of Equity
24th Oct 20184:52 pmRNSDirector/PDMR Shareholding
17th Oct 20185:49 pmRNSIssue of Equity
15th Oct 201812:38 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
12th Oct 20182:52 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
11th Oct 20184:42 pmRNSIssue of Equity
11th Oct 20187:01 amRNSCrystallisation of business unit & issue of shares
11th Oct 20187:00 amRNSAUM Update
3rd Oct 201810:24 amRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
19th Sep 201811:52 amRNSForm 8.3 - Jardine Lloyd Thompson Group
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
17th Aug 20189:27 amRNSDirectorate Change
6th Aug 20187:00 amRNSBlock listing Interim Review
1st Aug 20187:00 amRNSTotal Voting Rights
31st Jul 20185:57 pmRNSIssue of Equity
31st Jul 201811:29 amRNSDirector/PDMR Shareholding
25th Jul 20183:38 pmRNSDirectorate Change
25th Jul 20183:26 pmRNSResult of AGM
19th Jul 201811:13 amRNSForm 8.3 - Consort Medical Plc
18th Jul 20184:21 pmRNSDirector/PDMR Shareholding
18th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
17th Jul 201810:58 amRNSForm 8.3 - Consort Medical Plc
16th Jul 20183:44 pmRNSDirector/PDMR Shareholding
12th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
12th Jul 20187:00 amRNSAuM Update
11th Jul 201811:06 amRNSForm 8.3 - Consort Medical Plc
3rd Jul 20186:27 pmRNSHolding(s) in Company
3rd Jul 20186:20 pmRNSIssue of Equity
3rd Jul 201812:07 pmRNSForm 8.3 - Consort Medical Plc
2nd Jul 201810:23 amRNSTotal Voting Rights
29th Jun 20187:00 amRNSBlock Listing Application
28th Jun 20185:55 pmRNSAnnual Financial Report
25th Jun 20187:00 amRNSGroup Audited Results for year ended 31 March 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.